The Eldridge BBB-B CLO ETF (CLOZ) remains a recommended buy, providing an estimated 6.8% annual yield with monthly income distributions. It has shifted its portfolio towards higher-quality BBB CLOs to reduce risk, though it has underperformed peers year-to-date due to higher exposure to BB tranches. Despite this, its assets under management have grown, signaling renewed investor confidence following the recent Federal Reserve meeting. Key risks include potential rising CLO defaults, which could impact capital appreciation given CLOZ's larger BB tranche allocation compared to benchmarks and competitors.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
